Oncotarget

Reviews:

LncRNA UCA1 in anti-cancer drug resistance

Haohao Wang, Zhonghai Guan, Kuifeng He, Jiong Qian, Jiang Cao and Lisong Teng _

PDF  |  HTML  |  How to cite

Oncotarget. 2017; 8:64638-64650. https://doi.org/10.18632/oncotarget.18344

Metrics: PDF 3017 views  |   HTML 4459 views  |   ?  


Abstract

Haohao Wang1,2, Zhonghai Guan1, Kuifeng He1,2, Jiong Qian1, Jiang Cao3 and Lisong Teng1,2

1Cancer Center, The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China

2Key Laboratory of Precision Diagnosis and Treatment for Hepatobiliary and Pancreatic Tumor of Zhejiang Province, Hangzhou, Zhejiang, P.R. China

3Clinical Research Center, The Second Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, P.R. China

Correspondence to:

Lisong Teng, email: [email protected]

Keywords: long non-coding RNA, UCA1, chemoresistance, cancer

Received: February 28, 2017     Accepted: May 22, 2017     Published: June 02, 2017

ABSTRACT

The pivotal role of the long non-coding RNA (lncRNA) urothelial carcinoma associated 1 (UCA1) in anti-cancer drug resistance has been confirmed in many cancers. Overexpression of lncRNA UCA1 correlates with resistance to chemotherapeutics such as cisplatin, gemcitabine, 5-FU, tamoxifen, imatinib and EGFR-TKIs, whereas lncRNA UCA1 knockdown restores drug sensitivity. These studies highlight the potential of lncRNA UCA1 as a diagnostic and prognostic biomarker, and a therapeutic target in malignant tumors. In this review, we address the role of lncRNA UCA1 in anti-cancer drug resistance and discuss its potential in future clinical applications.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 18344